Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT05378919 by Lithuanian University of Health Sciences, with a registry enrolment figure of 250 participants, started 2015-06-01 and due to reach its primary completion in 2025-06-01. Interventions recorded: Radiotherapy 50 Gy; Fluorouracil/folic acid; Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4); Radiotherapy 50 Gy. Conditions listed: Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX. Primary outcome: disease-free survival. Colorectal eligibility wording from the registry: "* diagnosed with rectal adenocarcinoma;". Sites: Lithuania. No results are recorded here; the registry entry is the source.